Company Overview of Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its prescription drug candidates includes PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. In addition, it develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. Further, the company is developing over-the-counter pharmaceuticals, i...
7327 Oak Ridge Highway
Knoxville, TN 37931
Founded in 2002
Key Executives for Provectus Biopharmaceuticals, Inc.
Total Annual Compensation: $500.0K
Co-Founder, Chief Technology Officer & Director
Total Annual Compensation: $500.0K
Interim Chief Financial Officer
Total Annual Compensation: $158.5K
Compensation as of Fiscal Year 2016.
Provectus Biopharmaceuticals, Inc. Key Developments
Provectus Biopharmaceuticals, Inc. Announces Preliminary Results from Phase 1b Trial of Intralesional PV-10 in Combination with KEYTRUDA® (Pembrolizumab)
Oct 18 17
Provectus Biopharmaceuticals, Inc. announced that results from the company’s ongoing Phase 1b/2 study of IL PV-10 in combination with KEYTRUDA® (pembrolizumab), Merck’s systemic anti-PD-1 (programmed death receptor-1) antibody agent, were presented at the Society for Melanoma Research 2017 Congress, held in Brisbane, Australia from October 18-21. IL injection of PV-10 induces immunogenic cell death that results in tumor-specific reactivity in circulating CD8+ T cells. The Phase 1b portion of the study continues to enroll patients with metastatic melanoma at clinical sites in the U.S. and Australia (NCT02557321); Stage IV patients with at least one injectable lesion who are candidates for KEYTRUDA are eligible. A total of up to 24 patients would receive the combination of IL PV-10 and KEYTRUDA every three weeks for five cycles (i.e., for up to 12 weeks, with no further PV-10 administered after week 12), followed by only KEYTRUDA every three weeks for up to 24 months. The primary endpoint for the Phase 1b trial is safety and tolerability; objective response rate and progression-free survival are key secondary endpoints (both assessed via RECIST 1.1 after five treatment cycles, and then every 12 weeks thereafter). IL PV-10 Results from the Phase 1b Trial Presented at SMR: Baseline characteristics (safety population, N=12): 92% men; median age of 71.5 years (range 28-81), 67% > 65 years; 67% Stage IV M1b/c. Subject characteristics (safety population): 2.5 median number of cutaneous/subcutaneous lesions (range 1-40); patients had substantial non-injected systemic disease burden in addition to their injectable cutaneous and/or subcutaneous lesions; patients received a median of 5 cycles of PV-10 (mean 3.8, range 1-5); PV-10 was not administered after week 12. Preliminary safety (safety population): adverse events were consistent with the established patterns for each drug; there were no unexpected toxicities or evidence of compounded toxicity. Preliminary target lesion efficacy (efficacy evaluable population, N=10): 50% complete response; 80% objective response; maximum response. Preliminary overall efficacy (efficacy evaluable population): 10% complete response; 50% objective response; 60% clinical benefit; responses observed in M1c patients; per RECIST 1.1.
Provectus Biopharmaceuticals, Inc., Annual General Meeting, May 30, 2017
Apr 27 17
Provectus Biopharmaceuticals, Inc., Annual General Meeting, May 30, 2017, at 16:00 US Eastern Standard Time. Agenda: To elect four directors to serve on board of directors for a one-year term; to conduct an advisory vote to approve the compensation of named executive officers; to approve, on an advisory basis, the frequency of the advisory vote on compensation of named executive officers; to ratify the selection of Marcum LLP as independent registered public accounting firm for 2017; to approve an amendment of the Certificate of Incorporation, as amended, to increase the number of authorized shares of preferred stock; and to approve an amendment of the Provectus Equity Compensation Plan to allow for the grant of restricted stock awards.
Provectus Biopharmaceuticals To Be Removed From NYSE MKT
Apr 27 17
On April 21, 2017, the NYSE MKT LLC filed a Form 25 with the Securities and Exchange Commission (the “SEC”), notifying the SEC of the NYSE MKT’s intention to remove the shares of common stock of Provectus Biopharmaceuticals, Inc. and the Company’s class of warrants with an exercise price of $0.85 per share expiring June 19, 2020 from listing and registration on the NYSE MKT effective May 1, 2017, pursuant to the provisions of Rule 12d2-2(b) of the Securities Exchange Act of 1934, as amended. The NYSE MKT’s filing of the Form 25 followed the NYSE MKT Committee for Review’s determination on April 5, 2017 to affirm the January 31, 2017 decision of the NYSE MKT Listing Qualifications Panel to initiate delisting proceedings due to (i) the “abnormally low” trading price of the shares of the Common Stock and (ii) the Company’s noncompliance with Section 1003(a)(iii) of the NYSE MKT Company Guide (requiring stockholders’ equity of $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years). The Common Stock and Listed Warrants will continue to trade on the OTCQB following the delisting from the NYSE MKT under the trading symbols “PVCT” and “PVCTWS,” respectively. The Company can provide no assurance that the Common Stock and Listed Warrants will continue to trade on the OTCQB in the future.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 19, 2017
February 21, 2017